X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CF102 (namodenoson) is a orally bioavailable small molecule drug that binds to A3AR. It is being evaluated for the treatment of non-alcoholic steatohepatitis.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
Under the agreement, Can-fite will focus on their development of CF102 (namodenoson), which is a selective agonist at the A3 adenosine receptor, for the treatment of pancreatic cancer.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ewopharma AG
Deal Size: $42.7 million Upfront Cash: $2.2 million
Deal Type: Licensing Agreement January 30, 2024
Details:
Namodenoson is a small orally bioavailable drug that binds to the A3 adenosine receptor (A3AR). It was evaluated in Phase II trials for 2nd line treatment for hepatocellular carcinoma, & as a treatment for non-alcoholic fatty liver disease & non-alcoholic steatohepatitis.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
CF102 (namodenoson) is a small orally bioavailable drug that binds with high affinity and selectivity to the A3AR. It is being evaluated for the treatment of pancreatic cancer.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
CF102 (namodenoson) is a small orally bioavailable drug that binds with high affinity and selectivity to the A3AR. It is being evaluated for the treatment of pancreatic cancer.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
CF102 (namodenoson) is a small orally bioavailable drug that binds with high affinity and selectivity to the A3AR. It was evaluated in Phase II trials for two indications, for hepatocellular carcinoma, NAFLD and for NASH.
Lead Product(s): Namodenoson,Gemcitabine
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
CF102 (namodenoson) is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR).
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3AR. Namodenoson is being evaluated as a second line treatment for hepatocellular carcinoma in a pivotal Phase III study, and as a treatment for NASH in a Phase IIb study.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
Namodenoson induced a complete response with disappearance of all metastases in a patient who will now continue the treatment under a compassionate use program in Romania.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
CF102 (namodenoson) is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR),met endpoints including reduced liver fat content, anti-inflammatory effects, and decreased body weight with excellent safety.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
CF102 (namodenoson), a small orally bioavailable drug that specifically binds to the A3 adenosine receptor (A3AR), over-expressed in liver cancer but not normal cells, is headed into a Phase III liver cancer pivotal trial.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Namodenoson, a small orally bioavailable drug that binds with high affinity and selectivity to A3 adenosine receptor, was evaluated in Phase II trials for two indications, as a second-line treatment for hepatocellular carcinoma, NAFLD and NASH.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
Details:
Can-Fite’s Namodenoson, a small orally bioavailable drug that binds with high affinity and selectivity to A3AR, was recently found to clear all cancer lesions in a patient treated under an Open Label Extension program of its concluded Phase II study for the treatment of HCC.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2021
Details:
CF102 (Namodenoson) experienced a Complete Response in Phase II study for the treatment of hepatocellular carcinoma, meaning that all cancer lesions have cleared. Company will now demonstrate Namodenoson’s efficacy in upcoming pivotal Phase III study.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2021
Details:
Company presented CF102 a highly specific and selective agonist at the A3 adenosine receptor to inhibit the growth of HEP-3b hepatocellular carcinoma cells.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Details:
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR)for the treatment of Liver Cancer and NASH.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2021
Details:
Patients will be randomized to oral treatment with either 25 mg Namodenoson or matching placebo given twice daily. The primary efficacy endpoint of the trial is overall survival.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2021
Details:
Can-Fite has received clearance from the Israeli Ministry of Health to commence a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
In the trial Namodenoson continues to demonstrate a good safety profile and is well tolerated with no severe adverse events reported.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
Anti-Inflammatory effect – a significant decrease in the liver enzymes ALT and AST and significant improvement in the positive cytokine adiponectin was recorded in the Namodenoson 25 mg treated group.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
In a Phase II NASH/NAFLD study, Namodenoson at the 25 mg dose produced statistically significant results showing anti-inflammatory, anti-steatotic, and anti-fibrosis effects in the liver, while also having a strong safety profile and being well tolerated.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Can-Fite’s Phase II NAFLD/NASH dose-finding study, assessing the efficacy and safety of Namodenoson (CF102), achieved its endpoints in a dose dependent and statistically significant manner.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Patent claims include use of the A3 adenosine receptor (A3AR), the target of Can-Fite’s platform technology, in reducing ectopic fat accumulation particularly in fatty liver as manifested in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Results confirm 25 mg Namodenoson as optimal dose based on MRI-PDFF analysis and liver enzymes, reduction of liver fibrosis and resolving all cases of NASH; Namodenoson continues to demonstrate a very good safety profile after drug treatment.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
Can-Fite has successfully concluded a meeting with the Scientific Advice Working Party (SAWP) of the European Medicines Agency regarding Phase III development of its drug candidate Namodenoson in the treatment of hepatocellular carcinoma, the most common form of liver cancer.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
Patent allowance follows compelling Phase II data showing Namodenoson resolved all cases of NASH after 12 weeks of treatment, and it reduced hepatic fibrosis and steatosis in NAFLD and NASH patients.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
All cases of NASH significantly resolved after 12 weeks of treatment with Namodenoson 25 mg.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
The study shows Namodenoson has therapeutic effects with a good safety profile and is a very strong candidate for continued clinical development in the treatment of NAFLD/NASH.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2020
Details:
Namodenoson may create powerful combination treatment with checkpoint inhibitors.
Lead Product(s): Namodenoson,Pembrolizumab,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2020
Details:
Chong Kun Dang Pharmaceuticals (CKD) of South Korea, has licensed the distribution rights to Namodenoson in South Korea for the treatment of liver cancer and NASH.
Lead Product(s): Namodenoson
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chong Kun Dang Pharm
Deal Size: $8.0 million Upfront Cash: $6.0 million
Deal Type: Licensing Agreement February 18, 2020
Details:
The Phase III pivotal trial will evaluate the efficacy of its drug candidate Namodenoson in patients with advanced hepatocellular carcinoma.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
Details:
Can-Fite’s completed Phase II liver cancer study found that Namodenoson increased overall survival in HCC patients with Child Pugh B7.
Lead Product(s): Namodenoson
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
